August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is John, and I'll be your conference ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with ...

With heavy hearts, we announce the peaceful passing of Mary Eldean O’Hearn, fondly known as Eldean or Deanie, on July 29, ...

Cerebral palsy (CP) is a neurological disorder that affects movements, coordination and muscle tone. This paper presents a neural network model having three modules for classifying walking patterns ...

The Lubavitcher Rebbe echoed this with the idea of “descent for the purpose of ascent.” The decline in physical and cognitive ...

Discover Amylyx Pharmaceuticals' Q2 2025 updates, including Avexitide's Phase III progress for PBH, upcoming PSP trial results, and a strong cash ...

DelveInsight's Progressive Supranuclear Palsy Market Insights report includes a comprehensive understanding of current ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

(Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the second quarter ended June 30, 2025. "As we look ahead to the second half of the year and into 2026, we ...

Neurorehabilitation: Transforming lives via interdisciplinary approach for atypical Parkinsonism: Dr. Vignesh Srinivasan & Dr. Poovarasan Wednesday, August 6, 2025, 08:00 Hrs [IST ...

Wavebreak Therapeutics LLC has identified thiazole compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of amyloidosis, Creutzfeldt-Jakob disease, ...